Lloyd Singh charged with selling unregistered drug to GPHC
The Chief Executive Officer (CEO) of the International Pharmaceutical Agency (IPA) was today charged for selling unregistered drugs to the Georgetown Public Hospital Corporation (GPHC).
Lloyd Singh appeared before Magistrate Judy Latchman charged with selling the drug – Rituximab (Maball) – which is a drug used to treat Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia and other indications such as Rheumatoid Arthritis.
The court heard that Singh of Lot 226 ‘B’ Camp Street on August 12, 2017 sold and supplied the unregistered drug to the GPHC, in violation of the Food and Drugs Regulation.
He is also charged for selling the drugs again on October 23, 2017 to the same entity.
He was released on $30,000 bail on each charge and the matter is adjourned to July 27.
The Food and Drug Act of 1971 and Regulation 1977 states that every new drug/pharmaceutical must be registered, and Regulation 48 stipulates that all drugs/pharmaceuticals must be properly packaged and labelled.